Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. Issue 7 (3rd May 2021)

• Record Type: Journal Article
• Authors: Lam, Marion; Touitou, Valérie; Choquet, Sylvain; Cassoux, Nathalie; Ghesquières, Hervé; Kodjikian, Laurent; Schmitt, Anna; Gattoussi, Sarra; Tabouret, Émeline; Sampo, Magali; Blonski, Marie; Angioi‐Duprez, Karine; Houot, Roch; Mouriaux, Frédéric; Gyan, Emmanuel; Le Lez, Marie‐Laure; Moles, Marie‐Pierre; Croisé, Fabien; Chauchet, Adrien; Schwartz, Claire; Ahle, Guido; Meyer, Laurent; Gressin, Rémy; Chiquet, Christophe; Oberic, Lucie; Ollé, Priscille; Marolleau, Jean‐Pierre; Jany, Benjamin; Tempescul, Adrian; Cochener, Béatrice; Damaj, Gandhi; Quintyn, Jean‐Claude; Moluçon‐Chabrot, Cécile; Rousseau, Eve; Franciane, Paul; Schneider, Christelle; Massé, Hélène; Tamburini‐Bonnefoy, Jérôme; Brézin, Antoine; Fornecker, Luc‐Matthieu; Ballonzoli, Laurent; Le Garff‐Tavernier, Magali; Hoang‐Xuan, Khê; Bodaghi, Bahram; Soussain, Carole; Houillier, Caroline;
• Is Part Of: American journal of hematology. Volume 96:Issue 7(2021)
• Page Start: 823
• Page End: 833
• Publication Date: 2021-05-03
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.26199
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high‐dose methotrexate (IV HD‐MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first‐line treatment with HD‐MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL‐10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL‐10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow‐up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression‐free survival, ocular‐free survival and brain‐free survival were 75, 18, 29 and 73 months, respectively. IV HD‐MTX based systemic therapy as a first‐line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL‐10.